Axsome Therapeutics, Inc.
NASDAQ:AXSM
90.07 (USD) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 270.6 | 50.037 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 32.899 | 5.198 | 1.156 | 0.078 | 0.037 | 0.049 | 0.043 | 0.02 | 0.004 | 0 | 0 |
| Gross Profit
| 237.701 | 44.84 | -1.156 | -0.078 | -0.037 | -0.049 | -0.043 | -0.02 | -0.004 | 0 | 0 |
| Gross Profit Ratio
| 0.878 | 0.896 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 97.485 | 57.947 | 58.061 | 70.245 | 53.647 | 23.495 | 19.958 | 21.2 | 6.777 | 4.279 | 1.535 |
| General & Administrative Expenses
| 222.823 | 123.954 | 66.646 | 28.897 | 13.598 | 9.352 | 7.207 | 6.344 | 2.419 | 1.393 | 0.304 |
| Selling & Marketing Expenses
| 100.3 | 35.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 323.123 | 159.254 | 66.646 | 28.897 | 13.598 | 9.352 | 7.207 | 6.344 | 2.419 | 1.393 | 0.304 |
| Other Expenses
| 55.293 | 4.139 | 0 | -0.054 | -0.139 | 0.217 | 0.207 | 0.474 | 0 | -0.184 | 0 |
| Operating Expenses
| 420.608 | 221.34 | 124.707 | 99.088 | 67.106 | 32.629 | 26.957 | 27.069 | 9.196 | 5.488 | 1.839 |
| Operating Income
| -182.907 | -176.501 | -124.707 | -99.141 | -67.245 | -32.847 | -27.164 | -27.544 | -9.196 | -5.672 | -1.839 |
| Operating Income Ratio
| -0.676 | -3.527 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -55.371 | -10.633 | -5.696 | -3.759 | -1.1 | 2.791 | -0.646 | 0.474 | -2.278 | -2.746 | -0.327 |
| Income Before Tax
| -238.278 | -187.134 | -130.403 | -102.901 | -68.345 | -30.965 | -28.943 | -27.202 | -10.56 | -6.001 | -2.167 |
| Income Before Tax Ratio
| -0.881 | -3.74 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.96 | 10.633 | 4.54 | 2.488 | 1.342 | 3.008 | 1.298 | 0.586 | 1.36 | -2.417 | -1.839 |
| Net Income
| -239.238 | -197.766 | -134.943 | -105.389 | -69.687 | -30.965 | -28.943 | -27.202 | -10.56 | -6.001 | -2.167 |
| Net Income Ratio
| -0.884 | -3.952 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -5.27 | -4.86 | -3.59 | -2.83 | -2.05 | -1.15 | -1.27 | -1.42 | -0.88 | -0.47 | -0.17 |
| EPS Diluted
| -5.27 | -4.86 | -3.59 | -2.83 | -2.05 | -1.15 | -1.27 | -1.42 | -0.88 | -0.47 | -0.17 |
| EBITDA
| -176.073 | -170.937 | -124.707 | -99.088 | -67.106 | -32.629 | -26.957 | -27.069 | -6.918 | -2.742 | -1.839 |
| EBITDA Ratio
| -0.651 | -3.416 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |